B L Lum

2.3k total citations
33 papers, 1.9k citations indexed

About

B L Lum is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, B L Lum has authored 33 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in B L Lum's work include Drug Transport and Resistance Mechanisms (10 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer therapeutics and mechanisms (6 papers). B L Lum is often cited by papers focused on Drug Transport and Resistance Mechanisms (10 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer therapeutics and mechanisms (6 papers). B L Lum collaborates with scholars based in United States, Switzerland and United Kingdom. B L Lum's co-authors include Branimir I. Šikić, Frank M. Torti, George A. Fisher, Joanne Halsey, N A Brophy, Michael P. Gosland, Edwin L. Alderman, A. J. Patek, Francisco J. Plaza Martín and Sonja Kaubisch and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

B L Lum

33 papers receiving 1.8k citations

Peers

B L Lum
Sanford Kempin United States
Lloyd E. Damon United States
Prasad Mathew United States
Ronald G. Stoller United States
Michael E. Ross United States
Chatchada Karanes United States
Karen Seiter United States
Thomas Licht Germany
Ramzi Dagher United States
Samuel A. Jacobs United States
Sanford Kempin United States
B L Lum
Citations per year, relative to B L Lum B L Lum (= 1×) peers Sanford Kempin

Countries citing papers authored by B L Lum

Since Specialization
Citations

This map shows the geographic impact of B L Lum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B L Lum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B L Lum more than expected).

Fields of papers citing papers by B L Lum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B L Lum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B L Lum. The network helps show where B L Lum may publish in the future.

Co-authorship network of co-authors of B L Lum

This figure shows the co-authorship network connecting the top 25 collaborators of B L Lum. A scholar is included among the top collaborators of B L Lum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B L Lum. B L Lum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jackisch, Christian, S.-B. Kim, Semiglazov Vf, et al.. (2014). Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Annals of Oncology. 26(2). 320–325. 86 indexed citations
2.
3.
Graham, Richard, Sravanthi Cheeti, Luca Matassa, et al.. (2010). Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. Journal of Chromatography B. 878(9-10). 785–790. 35 indexed citations
4.
Graham, Richard, Ilsung Chang, Karin Jorga, et al.. (2010). Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects.. Journal of Clinical Oncology. 28(15_suppl). e13009–e13009. 1 indexed citations
5.
Advani, Ranjana H., B L Lum, George A. Fisher, et al.. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Annals of Oncology. 16(12). 1968–1973. 16 indexed citations
6.
7.
Advani, Ranjana H., George A. Fisher, B L Lum, et al.. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.. PubMed. 7(5). 1221–9. 62 indexed citations
8.
Advani, Ranjana H., Giuseppe Visani, D Milligan, et al.. (1999). Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) Plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC). Advances in experimental medicine and biology. 457. 47–56. 33 indexed citations
9.
Rosenthal, David I., Pamela Nurenberg, Carlos Becerra, et al.. (1999). A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.. PubMed. 5(4). 739–45. 94 indexed citations
10.
Berry, Gerald J., Margaret E. Billingham, Edwin L. Alderman, et al.. (1998). The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Annals of Oncology. 9(7). 711–716. 203 indexed citations
11.
12.
Fisher, George A., et al.. (1996). Pharmacological considerations in the modulation of multidrug resistance. European Journal of Cancer. 32(6). 1082–1088. 115 indexed citations
13.
Lum, B L, et al.. (1995). Comparison of Three Methods for Cyclosporine Area Under the Curve Monitoring Calculations. Therapeutic Drug Monitoring. 17(3). 305–307. 10 indexed citations
14.
Bartlett, Nancy L., B L Lum, George A. Fisher, et al.. (1994). Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.. Journal of Clinical Oncology. 12(4). 835–842. 161 indexed citations
15.
Cooney, Gerard F., et al.. (1994). Absolute Bioavailability and Absorption Characteristics of Aerosolized Tobramycin in Adults with Cystic Fibrosis. The Journal of Clinical Pharmacology. 34(3). 255–259. 48 indexed citations
16.
Fisher, George A., Joanne Halsey, B L Lum, et al.. (1994). A phase I study of paclitaxel (taxol®) (T) in combination with SDZ PSC 833, a potent modulator of multidrug resistance (MDR). Anti-Cancer Drugs. 5. 43–43. 6 indexed citations
17.
Fisher, George A., N A Brophy, Joanne Halsey, et al.. (1992). Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.. Journal of Clinical Oncology. 10(10). 1624–1634. 192 indexed citations
18.
Lum, B L & Frank M. Torti. (1991). Adjuvant Intravesicular Pharmacotherapy for Superficial Bladder Cancer. JNCI Journal of the National Cancer Institute. 83(10). 682–694. 66 indexed citations
19.
Torti, Frank M., et al.. (1987). Superficial bladder cancer: the primacy of grade in the development of invasive disease.. Journal of Clinical Oncology. 5(1). 125–130. 64 indexed citations
20.
Torti, Frank M. & B L Lum. (1984). The biology and treatment of superficial bladder cancer.. Journal of Clinical Oncology. 2(5). 505–531. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sanford Kempin Breakdown of academic impact, for papers by Lloyd E. Damon Breakdown of academic impact, for papers by Prasad Mathew Breakdown of academic impact, for papers by Ronald G. Stoller Breakdown of academic impact, for papers by Michael E. Ross Breakdown of academic impact, for papers by Chatchada Karanes Breakdown of academic impact, for papers by Karen Seiter Breakdown of academic impact, for papers by Thomas Licht Breakdown of academic impact, for papers by Ramzi Dagher Breakdown of academic impact, for papers by Samuel A. Jacobs
Rankless by CCL
2026